SCHEMBL238571

SCHEMBL238571

Cc1cc2ncc3cc(-c4ccc(Cl)cc4)c(Cl)nc3n2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.61
RAB9A P51151 11/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
HPGD P15428 5/20 0.61
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
TP53 P04637 4/20 0.61
MAPT P10636 5/20 0.42
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.39
HTT P42858 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL237892 0.90 RAB9A (0.49) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL234727 0.90 NPC1 (0.49) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL235881 0.90 RAB9A (0.48) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL238454 0.89 HTT (0.49) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL239177 0.88 NPC1 (0.47) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL237538 0.87 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL239031 0.86 NPC1 (0.51) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL238620 0.84 NPC1 (0.43) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL2755334 0.83 NPC1 (0.43) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL236385 0.83 DYRK3 (0.43) NPC1RAB9ASMN1; SMN2HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.